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INTRODUCTION

CHOOSING A DONOR

PERFORMING THE TRANSPLANT

There are many indications for hematopoietic stem cell transplantation.
In addition to hematologic malignancies, transplants are performed in
certain non-hematologic malignancies, for marrow disorders such as Sickle
Cell Anemia, and for various inherited disorders such as SCID.
Traditionally, transplants have been performed between donors and
recipients that are a complete HLA match (typically matched siblings). That
is, patients have identical HLA alleles on both copies of chromosome 6.
HLA alleles code for major histocompatibility
complex molecules, which are the proteins
that cause transplant rejection when a
mismatch between donor and recipient is
present. Thus, matched transplants have
been historically favored in order to avoid
both rejection of the graft by the recipient,
as well as disease in the recipient due to
graft vs. host disease (GVHD) in which the donor immune cells attack the
host’s tissues.
However, matched transplants have several disadvantages. First, only
about 30% of patients requiring a transplant have a matched sibling
available as a donor. For the remaining 70%, the search for an unrelated
matched donor can be time consuming, expensive, and especially difficult
for patients of minority racial and ethnic groups. Many conditions requiring
transplant are so acute that patients often die during the search for a donor.
Accordingly, several institutions pioneered the research and implementation
of haploidentical transplants as a viable option.
A haploidentical transplant refers to the situation when the recipient and
donor have identical alleles on one copy of chromosome 6, but not on the
other. In terms of advantages, haploidentical transplants greatly increase
the pool of available donors since biological parents are by definition
haploidentical to all of their children, and there is a much greater chance
that a sibling will be a half match than a full match. Additionally,
haploidentical transplants allow for a critical Graft vs. Tumor effect (GVT),
whereby the donor’s immune cells attack the recipient’s cancer cells
because of the HLA mismatch present. The caveat, however, is that this
mismatch also promotes GVHD that can be lethal. Accordingly, different
institutions have attempted various methods of manipulating the donor graft
to try and maximize the GVT effect while minimizing GVHD. Jefferson’s
regimen is one such method that has had success thus far.

Jefferson takes many factors into account when choosing a suitable
haploidentical donor. Three particularly important criteria are (1) the
donor’s HLA profile, (2) the presence of KIR ligand mismatch
between donor and recipient, and (3) the implications of pregnancyinduced immunologic effects.

Jefferson’s method is myeloablative with respect to the donor’s bone
marrow and T-cell replete with respect to the donor graft. It is a two-step
process, meaning that the myeloid and lymphoid lineages are infused
separately. The goals of this method are as follows:
1. Provide optimal T-cell dose (maximize GVT, minimize GVHD, avoid graft
failure)
2. Avoid exposure of HSCs to Cyclophosphamide to prevent potential cell
damage
3. Avoid polarization of T cells to TH2 phenotype

HLA Typing
HLA typing is the most important
component of picking a donor. It is done
via a blood test, and the results look
like the example on the right. By looking
at the pattern of inheritance of HLA alleles, one can deduce the
chromosomal makeup of the patient’s parents and siblings. In this example,
all but one of the patient’s tested family members is at least a half match,
thus allowing selection of a donor based on even more specific criteria. This
is illustrative of one of the main advantages of haploidentical transplant.

KIR Ligand Mismatch
KIR receptors are present on Natural
Killer (NK) Cells, and their ligands are
MHC-I proteins. When an NK cell
encounters a self MHC-I molecule, it’s killing function is inhibited.
Conversely, when it encounters non-self MHC-I, it causes cell lysis. Thus, a
mismatch between donor and recipient results in lysis of recipient cells by
donor NK cells. Interestingly, donor NK cells preferentially kill blood cells but
not tissue cells. Thus, KIR mismatch between donor and recipient causes a
GVT effect, but no GVHD. This effect is especially robust in AML patients.

Pregnancy-Induced Immunologic Effects
As a result of exposure to each
others’ antigens in utero, the
immune systems of mother
and child react to each other in
unique ways. Furthermore,
women who have carried a male
child have antibodies to Ychromosome antigens. Donors are
thus picked to maximize the potential GVT effect based on these variables.

Days -9 to -7: Patient is subjected to
total body irradiation (TBI; 12 Gy) to
reduce the amount of cancer cells and suppress the immune system to
prevent graft rejection. This regimen is considered myeloablative.
Day -6: Patient receives 2x108 T-cells/kg (Step 1). The protocol was designed
so that this dose could be adjusted as necessary, but the dose was not
changed due to high rates of engraftment, good immune reconstitution, and low
rates of GVHD.
Days -5 and -4: Rest. Patients develop high fevers, diarrhea, and rash as a
result of the T-cell infusion.
Days -3 and -2: Cyclophosphamide (Cy) administration. Cy targets rapidly
dividing cells, and thus selectively kills the infused alloreactive T-cells while
sparing non-alloreactive T-cells. Fevers disappear after the second dose of Cy.
Day -1: Rest. Patient is given additional GVHD prophylaxis.
Day 0: Infusion of hematopoietic stem cells (Step 2)

RESULTS AND FUTURE IMPLICATIONS
To date, over 180 patients have received this type of transplant at
Jefferson. Patients have experienced low incidences of severe GVHD,
relapse, and infection, and in general results have been comparable
to those received with fully matched transplants. This will potentially allow
virtually every patient in need of a transplant to receive one, and will widen
the spectrum of diseases that can be treated with such methods.
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